Free
Meeting Abstracts  |   May 2006
The Common Inhalation Anesthetic Isoflurane Induces Apoptosis and Increases Amyloid β Protein Levels
Author Affiliations & Notes
  • Zhongcong Xie, M.D., Ph.D.
    *
  • Yuanlin Dong, M.D., M.S.
  • Uta Maeda
  • Paul Alfille, M.D.
    §
  • Deborah J. Culley, M.D.
  • Gregory Crosby, M.D.
    #
  • Rudolph E. Tanzi, Ph.D.
    **
  • * Assistant Professor, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. Member, Division of Aging, Harvard Medical School, Boston, Massachusetts. † Research Technologist, ‡ College Student, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. § Assistant Professor, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston, Massachusetts. ∥ Assistant Professor, # Associate Professor, Department of Anesthesia, Harvard Medical School, Brigham & Women’s Hospital, Boston, Massachusetts. Member, Division of Aging, Harvard Medical School, Boston, Massachusetts. ** Professor, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. Member, Division of Aging, Harvard Medical School, Boston, Massachusetts.
Article Information
Meeting Abstracts   |   May 2006
The Common Inhalation Anesthetic Isoflurane Induces Apoptosis and Increases Amyloid β Protein Levels
Anesthesiology 5 2006, Vol.104, 988-994. doi:
Anesthesiology 5 2006, Vol.104, 988-994. doi:
THE excessive accumulation of the β-amyloid protein (Aβ), generated via  sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretase, is a key pathogenic event in Alzheimer disease (AD)1 (reviewed in Tanzi and Bertram2). Increasing evidence indicates that apoptosis is associated with variety of neurodegenerative disorders, including AD3–6 (reviewed in Raina et al.  7). Several studies have also suggested that perioperative factors, such as hypoxia,8–12 hypocapnia,13 and anesthetics14 may contribute to AD neuropathogenesis. Isoflurane, a commonly used inhalation anesthetic, has previously been reported to promote Aβ oligomerization and cytotoxicity in pheochromocytoma cells.14 However, the effects of isoflurane on APP processing and Aβ generation have not been previously determined. To investigate a possible role for isoflurane in AD pathogenesis as well as postoperative cognitive dysfunction (POCD), we investigated whether a clinically relevant concentration (2%) of isoflurane can induce apoptosis, alter APP processing, and increase Aβ generation in H4 human neuroglioma cells overexpressing human APP.
Materials and Methods
Cell Lines
We used naive H4 human neuroglioma cells stably transfected to express the APP full-length (FL) (H4-APP-FL cells) and APP-C99 (H4-APP-C99 cells) in the experiments. All cell lines were cultured in Dulbecco’s Modified Eagle Medium (high glucose) containing 9% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mm L-glutamine. Stably transfected H4 cells were in addition supplemented with 200 μg/ml G418.
Cell Treatment
Twenty-one percent O2, 5% CO2, and 2% isoflurane were delivered from an anesthesia machine to a sealed plastic box in a 37°C incubator containing six-well plates seeded with one million cells in 1.5 ml cell culture media. A Datex infrared gas analyzer (Puritan-Bennett, Tewksbury, MA) was used to continuously monitor the delivered carbon dioxide, oxygen, and isoflurane concentrations. We treated the cells with 2% isoflurane for 6 h, during which time the cells were incubated in serum-free media. In the interaction studies, the cells were treated with 250 nm N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), 100 μm benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD), 15 μm Aβ, 50 ng/ml 6E10, and 50 ng/ml 4G8 1 h before the treatment with 2% isoflurane. Control conditions included 5% CO2plus 21% O2, which did not affect caspase-3 activation, cell viability, APP processing, or Aβ generation (data not shown).
Cell Lysis and Protein Amount Quantification
Cell pellets were detergent-extracted on ice using immunoprecipitation buffer (10 mm Tris-HCl, pH 7.4, 150 mm NaCl, 2 mm EDTA, 0.5% Nonidet P-40) plus protease inhibitors (1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin A). The lysates were collected, centrifuged at 12,000 rpm for 10 min, and quantified for total proteins with use of a BCA protein assay kit (Pierce, Iselin, NJ).
Western Blot Analysis
The cells were harvested at the end of experiments and were subjected to Western blots as described by Xie et al.  15 Antibodies A8717 (1:1,000; Sigma, St. Louis, MO), 6E10 (1:200; Signet, Dedham, MA), and anti–β-actin (1:2,000; Sigma) were used to visualize APP-FL (110 kd), amyloid precursor protein C-terminal fragments (APP-CTFs; 10–12 kd), APP-C99 (10 kd), and β-actin (42 kd), respectively. A caspase-3 antibody (1:1,000 dilution; Cell Signaling Technology, Inc., Beverly, MA) was used to recognize caspase-3 fragment (17–20 kd) resulting from cleavage at aspartate position 175 and caspase-3 FL (35–40 kd). The quantitation of Western blots was performed as described by Xie et al.  15 
Quantitation of Aβ Using Sandwich Enzyme-linked Immunosorbent Assay
Secreted Aβ was measured with a sandwich enzyme-linked immunosorbent assay (ELISA) by using an Aβ measurement kit (Bioresource, Camarillo, CA) and by the Aβ ELISA Core Facility at Center for Neurologic Diseases, Harvard Institute of Medicine, Harvard Medical School, Boston, Massachusetts, as described by Xie et al.  16 Specifically, 96-well plates were coated with mouse monoclonal antibodies specific to Aβ40(Ab266) or Aβ42(21F12). After blocking with albumin, wells were incubated overnight at 4°C with test samples of conditioned cell culture media, and then an anti-Aβ (α-Aβ-HR1) conjugated to horseradish peroxidase was added. Plates were then developed with 3,3’,5,5’-tetramethylbenzidine reagent and well absorbance measured at 450 nm. Aβ levels in test samples were determined by comparison with signal from unconditioned media spiked with known quantities of Aβ40and Aβ42.
Cell Viability Study
The cell viability was determined by using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT; Sigma). The experiments were performed according to the company protocol. Briefly, we added 150 μl MTT solution to one well, containing 1.5 ml cell culture media, of a six-well plate. We then returned the cell culture to the incubator for 2 h. Finally, we removed the cell culture fluid and added 1.5 ml isopropanol into the wells. We spectrophotometrically measured the absorbance at a wavelength of 570 nm. We present the changes in the absorbance, as the number of cell viability, in the cells treated with isoflurane as the percentage of those in the cells treated with control conditions.
Statistics
Given the presence of background caspase-3 activation and cell death in cells cultured in serum-free media, we did not use absolute values to describe changes in caspase-3 activation and cell viability. Instead, changes in caspase-3 activation and cell viability were presented as a percentage of those of the control group. One hundred percent caspase-3 activation or cell viability refers to control levels for purposes of comparison to experimental conditions. We evaluated caspase-3 activation, cell viability, APP processing, and Aβ levels in the experimental and control cells with a blinded fashion. Data were expressed as mean ± SD. The number of samples varied from 4 to 10, and the samples were normally distributed. We used a two-tailed t  test to compare the difference between the experimental groups. P  values less than 0.05 (* or #) and 0.01 (** or ##) were considered statistically significant.
Results
2% Isoflurane Induces Apoptosis and Increases Levels of Secreted Aβ Levels
We first assessed whether control conditions, consisting of 5% CO2plus 21% O2and balanced nitrogen, can affect caspase-3 activation, cell viability, APP processing, and Aβ levels. We have found that there was no significant difference in caspase-3 activation, cell viability, APP processing, and Aβ levels in the cells exposed to control conditions versus  cells exposed to standard cell incubator conditions.
We then exposed H4 human neuroglioma cells stably transfected to express human full-length, wild-type APP (H4-APP-FL cells) to 2% isoflurane for 6 h. Because caspase-3 activation is one of the final steps of cellular apoptosis,17 we assessed the effects of isoflurane on caspase-3 activation by quantitative Western blot analyses. Two percent isoflurane induced caspase-3 activation in H4-APP-FL cells (figs. 1A and B) as evidenced by increased ratios of cleaved (activated) caspase-3 fragment (17–19 kd) to FL caspase-3 (35 kd). Immunoblotting for caspase-3 revealed increases in activated caspase-3 fragment and decreases in FL caspase-3 in H4-APP-FL cells treated with 2% isoflurane as compared with those treated with control conditions (fig. 1A). Quantitation of the ratio of cleaved (activated) versus  FL caspase-3 revealed that the isoflurane treatment led to a 249% increase in caspase-3 activation as compared with control conditions (fig. 1B; P  < 0.01). Two percent isoflurane treatment also decreased cell viability by 25% in H4-APP-FL cells (fig. 1C; P  < 0.05). These results indicate that a clinically relevant concentration (2%) of isoflurane can induce apoptosis in H4-APP-FL cells.
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
×
We next assessed the effects of 2% isoflurane on APP processing and Aβ generation in H4-APP-FL cells. Two percent isoflurane led to decreases in levels of APP-CTFs in H4-APP-FL cells as compared with those in the cells treated with control conditions (fig. 1D). In contrast, isoflurane treatment led to no significant differences in the amounts of APP-FL (fig. 1D). Quantitation of the ratio of APP-CTFs and APP-FL indicated that isoflurane treatment decreased the ratio of APP-CTFs to APP-FL by 60% as compared with control conditions (fig. 1E; P  < 0.05). We next tested whether decrease in levels of APP-CTFs after isoflurane treatment might be due to an increase in γ-secretase cleavage. γ-Secretase cleavage of the β-secretase–derived APP-CTF, APP-C99, would be expected to lead to increased levels of secreted Aβ. Therefore, we next measured levels of secreted Aβ after isoflurane treatment. Two percent isoflurane significantly increased the levels of both Aβ40(193 vs.  50 pg/ml) and Aβ42(83 vs.  24 pg/ml) by roughly threefold to fourfold as compared with control conditions (fig. 1F; P  < 0.05, P  < 0.01). These data suggest that treatment with 2% isoflurane leads to an increase in γ-secretase cleavage of APP-C99, as evidenced by increased levels of secreted Aβ.
We next set out to test whether enhanced caspase activation and apoptosis induced by isoflurane are dependent on increased production of Aβ. For this purpose, we incubated H4-APP-FL cells with anti-Aβ antibodies 6E10 (50 ng/ml) and 4G8 (also 50 ng/ml) for 1 h, followed by treatment with 2% isoflurane for 6 h. The anti-Aβ antibodies 6E10 and 4G8 decreased the amount of Aβ in the culture media (see Materials and Methods for Aβ assay details; data not shown), whereas levels of activated caspase-3 fragment were still increased in cells treated with 2% isoflurane or 2% isoflurane plus 6E10 and 4G8 as compared with control conditions (fig. 2A). Quantitation of the Western blots, based on the ratio of caspase-3 fragment to FL caspase-3, revealed that treatment with 2% isoflurane plus saline induced caspase-3 activation by 289% as compared with control conditions (fig. 2B; P  < 0.01). Likewise, treatment with 2% isoflurane plus anti-Aβ antibodies 6E10 and 4G8 still led to a 295% increase in caspase-3 activation as compared with the control (fig. 2B; P  < 0.01). Therefore, Aβ in the culture media does not seem to drive isoflurane-induced caspase-3 activation. As a positive control, the caspase inhibitor Z-VAD did attenuate caspase-3 activation induced by 2% isoflurane treatment (fig. 2A) by roughly 57% (fig. 2B; P  < 0.01).
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
×
We next tested whether isoflurane-induced caspase-3 activation depends on overexpression of FL-APP. For this purpose, we used H4 cells overexpressing APP-C99 (H4-APP-C99 cells). Immunoblotting for caspase-3 revealed a 320% increase in activated caspase-3 fragment in H4-APP-C99 cells treated with 2% isoflurane as compared with control conditions (figs. 3A and B; P  < 0.01). These results suggest that the isoflurane-induced apoptosis is not dependent on increased levels of APP-FL.
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
×
DAPT Potentiates Isoflurane-induced Apoptosis
Given the observations of decreased APP-CTFs and increased levels of secreted Aβ after isoflurane treatment in the H4-APP-FL cells, we next asked whether γ-secretase cleavage was required for isoflurane-induced caspase activation. For this purpose, the γ-secretase inhibitor DAPT, which increases the levels of APP-CTFs and decreases the levels of Aβ, was tested for effects on isoflurane-induced caspase-3 activation. As can be seen in figure 4A, activated caspase-3 fragment levels were increased after treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO), as compared with DMSO alone. DAPT alone had no effect on caspase activation but, as expected, did increase APP-CTFs levels (both APP-C83 and APP-C99; fig. 4A). Specifically, 2% isoflurane plus DMSO led to a 207% increase in caspase-3 activation and a roughly 45% decrease in APP-C83 and -C99 levels as compared with control conditions (fig. 4B; P  < 0.01). Interestingly, 2% isoflurane plus DAPT led to an even greater (50%) increase in caspase-3 activation than did treatment with 2% isoflurane plus DMSO (311% vs.  207%; figs. 4A and B; P  < 0.01). In addition, whereas isoflurane plus DMSO led to a roughly 45% decrease in both APP-CTFs, treatment with 2% isoflurane plus DAPT increased levels of APP-C83 (225%) and APP-C99 (174%) as compared with control conditions (figs. 4A and B; P  < 0.01). As expected, DAPT treatment also decreased Aβ levels (data not shown). These findings indicate that neither γ-secretase cleavage of APP nor increased secretion of Aβ is necessary for isoflurane-induced caspase activation in the H4-APP-FL cells. Treatment with DAPT plus isoflurane led to a greater degree of caspase activation than isoflurane, whereas DAPT alone did not induce caspase activation. Because treatment with DAPT plus isoflurane served to increase APP-CTFs levels, these data suggest that increased levels of APP-CTFs may enhance caspase activation independently of Aβ generation.
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
×
Discussion
We have shown for the first time that a clinically relevant concentration of isoflurane can induce apoptosis, alter APP processing (by decreasing APP-CTF levels), and increase Aβ levels in human H4 neuroglioma cells stably transfected with human FL-APP or APP-C99, whereas control conditions, consisting of 5% CO2plus 21% O2and balanced nitrogen, did not. Therefore, in addition to inducing apoptosis, isoflurane affects biosynthesis of a protein implicated in the pathogenesis of AD.
In agreement with our findings, even though isoflurane has been previously reported to protect against apoptosis,18–24 the opposite has also been reported.25–28 The difference could be due to the use of different cell lines, e.g.  , rat cardiac cells versus  human neural-derived cells, in these studies. The difference could be also due to the duration and concentration of isoflurane exposure. Isoflurane could protect against apoptosis at low concentrations but induce apoptosis at high concentrations. In future studies, we will assess the effects of isoflurane on apoptosis with different concentrations (e.g.  , 0.5 and 1% isoflurane) and durations (e.g.  , 1, 3, 12, and 24 h).
In the current study, isoflurane-induced caspase-3 activation could not be attenuated by reducing levels of Aβ in the culture media with either DAPT, a γ-secretase inhibitor, or the anti-Aβ antibodies 6E10 and 4G8. Interestingly, treatment with DAPT actually potentiated isoflurane-induced caspase-3 activation by roughly 1.5-fold, whereas DAPT treatment alone had no effect on caspase-3 activation. Isoflurane treatment alone decreased levels of APP-CTFs, whereas treatment with isoflurane plus DAPT served to increase levels of APP-CTFs by preventing γ-secretase-mediated proteolysis. Therefore, potentiation of isoflurane-induced caspase-3 activation by DAPT could be related to concurrent increases in APP-CTFs levels. One possible explanation is that caspase cleavage of APP-CTFs contributes to isoflurane-induced apoptosis. This would be consistent with the observation that APP-CTFs levels are decreased after treatment with isoflurane alone, because they likely undergo cleavage by caspase 3. Caspase cleavage of APP-CTFs has previously been reported to generate a short-lived, cytotoxic peptide called C31. C31 consists of the 31 C-terminal residues of APP.29,30 The APP antibodies used in this study to detect APP-CTFs would not detect APP-CTFs missing the C31 portion. Therefore, the observed decrease in APP-CTFs levels after the isoflurane treatment might be explained by caspase cleavage of APP-CTFs. In the case of the isoflurane plus DAPT treatment, increased levels of both APP-CTFs and caspase would be generated, potentially resulting in greater amounts of cytotoxic C31 peptide. Further investigation will be necessary to test this intriguing possibility as a mechanism underlying isoflurane-induced apoptosis.
Until now, it has remained unclear whether isoflurane-induced apoptosis is dependent on alterations in APP processing and Aβ production. We have observed that isoflurane can induce caspase-3 activation and apoptosis without affecting APP processing and Aβ generation in H4 naive cells, and we also found that DAPT treatment increases neither isoflurane-induced apoptosis nor levels of APP-CTFs in H4 naive cells (data not shown). These findings suggest that even though DAPT can potentiate isoflurane-induced apoptosis through concurrent increases in APP-CTF levels in H4-APP cells, the isoflurane-induced apoptosis may not be dependent on alterations in APP processing and Aβ production. The exact mechanism by which isoflurane induces apoptosis remains to be determined.
The clinical significance of these results is unknown. Aβ accumulates in the brain during normal aging and reaches especially high levels in AD, where it is believed to be a major pathogenic factor in the development of Alzheimer-type dementia. Other conditions associated with increased Aβ burden include Down syndrome, β-amyloid angiopathy, mutations in presenilin (a rare condition that is a risk factor for early-onset AD), and expression of apolipoprotein E-ϵ4, a vulnerability gene for late-onset AD that is present in at least one copy in roughly 25% of the population.2,31–34 Although our results would suggest that such individuals might be at increased risk for Aβ accumulation after isoflurane anesthesia, there is currently no evidence that isoflurane increases Aβ levels in vivo  or that it accelerates development of AD or alters its clinical expression.
One caveat of the current study is that there is currently no satisfactory way to extrapolate apoptosis findings in cultured cells to the in vivo  aging brain. Future studies will be required to determine the physiologic relevance of the current findings. This could be accomplished by delivering similar concentrations of isoflurane to AD transgenic mice and then assessing whether the treatment causes apoptosis and increased levels of Aβ in brain.
Nonetheless, our results have implications for understanding mechanisms of postoperative cognitive dysfunction13 and raise the possibility that isoflurane has adverse effects on APP and Aβ processing in the central nervous system. Additional studies seem warranted given the aging of the population and growing numbers of patients with AD who require surgery and general anesthesia.
The authors thank Weiming Xia, Ph.D. (Assistant Professor of Neurology at Aβ ELISA Core Facility, Center for Neurological Diseases, Harvard Institute of Medicine, Harvard Medical School, Boston, Massachusetts), for the measurement of Aβ levels. The authors thank Warren Zapol, M.D. (Reginald Jenney Professor of Anaesthesia), Keith Miller, Ph.D. (Mallinckrodt Professor of Pharmacology in the Department of Anaesthesia), and Stuart Forman, M.D., Ph.D. (Associate Professor of Anaesthesia in Department of Anesthesia and Critical Care), at Massachusetts General Hospital and Harvard Medical School, for their scientific discussion for the studies.
References
Glenner GG, Wong CW: Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885–90Glenner, GG Wong, CW
Tanzi RE, Bertram L: Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell 2005; 120:545–55Tanzi, RE Bertram, L
Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA: Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 1998; 57:1041–52Masliah, E Mallory, M Alford, M Tanaka, S Hansen, LA
Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, Vinters HV, Frautschy SA, Cole GM: Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer’s disease. Am J Pathol 1998; 152:379–89Yang, F Sun, X Beech, W Teter, B Wu, S Sigel, J Vinters, HV Frautschy, SA Cole, GM
Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW: Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999; 97:395–406Gervais, FG Xu, D Robertson, GS Vaillancourt, JP Zhu, Y Huang, J LeBlanc, A Smith, D Rigby, M Shearman, MS Clarke, EE Zheng, H Van Der Ploeg, LH Ruffolo, SC Thornberry, NA Xanthoudakis, S Zamboni, RJ Roy, S Nicholson, DW
Shimohama S, Tanino H, Fujimoto S: Changes in caspase expression in Alzheimer’s disease: Comparison with development and aging. Biochem Biophys Res Commun 1999; 256:381–4Shimohama, S Tanino, H Fujimoto, S
Raina AK, Hochman A, Ickes H, Zhu X, Ogawa O, Cash AD, Shimohama S, Perry G, Smith MA: Apoptotic promoters and inhibitors in Alzheimer’s disease: Who wins out? Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:251–4Raina, AK Hochman, A Ickes, H Zhu, X Ogawa, O Cash, AD Shimohama, S Perry, G Smith, MA
Kokmen E, Whisnant JP, O’Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46:154–9Kokmen, E Whisnant, JP O’Fallon, WM Chu, CP Beard, CM
Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, Joachim C, Litchfield S, Barnetson L, Smith AD: The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56:165–70Nagy, Z Esiri, MM Jobst, KA Morris, JH King, EM McDonald, B Joachim, C Litchfield, S Barnetson, L Smith, AD
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997; 277:813–7Snowdon, DA Greiner, LH Mortimer, JA Riley, KP Greiner, PA Markesbery, WR
Jendroska K, Hoffmann OM, Patt S: Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia. Ann N Y Acad Sci 1997; 826:401–5Jendroska, K Hoffmann, OM Patt, S
Kalaria RN: The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 2000; 21:321–30Kalaria, RN
Xie Z, Moir R, Romano DM, Tesco G, Kovacs D, Tanzi RE: Hypocapnia induces caspase-3 activation and increases A-beta production. Neurodegenerative Dis 2004; 1:29–37Xie, Z Moir, R Romano, DM Tesco, G Kovacs, D Tanzi, RE
Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF: Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101:703–9Eckenhoff, RG Johansson, JS Wei, H Carnini, A Kang, B Wei, W Pidikiti, R Keller, JM Eckenhoff, MF
Xie Z, Romano DM, Tanzi RE: Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type versus  FAD mutant forms of presenilin 1. J Mol Neurosci 2005; 25:67–77Xie, Z Romano, DM Tanzi, RE
Xie Z, Romano DM, Tanzi RE: RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via  differential effects on beta-amyloid precursor protein processing. J Biol Chem 2005; 280:15413–21Xie, Z Romano, DM Tanzi, RE
Thornberry NA: Caspases: Key mediators of apoptosis. Chem Biol 1998; 5:R97–103Thornberry, NA
Zaugg M, Jamali NZ, Lucchinetti E, Shafiq SA, Siddiqui MA: Norepinephrine-induced apoptosis is inhibited in adult rat ventricular myocytes exposed to volatile anesthetics. Anesthesiology 2000; 93:209–18Zaugg, M Jamali, NZ Lucchinetti, E Shafiq, SA Siddiqui, MA
Tyther R, Fanning N, Halligan M, Wang J, Redmond HP, Shorten G: The effect of the anaesthetic agent isoflurane on the rate of neutrophil apoptosis in vitro  . Ir J Med Sci 2001; 170:41–4Tyther, R Fanning, N Halligan, M Wang, J Redmond, HP Shorten, G
Wise-Faberowski L, Raizada MK, Sumners C: Oxygen and glucose deprivation-induced neuronal apoptosis is attenuated by halothane and isoflurane. Anesth Analg 2001; 93:1281–7Wise-Faberowski, L Raizada, MK Sumners, C
Wise-Faberowski L, Aono M, Pearlstein RD, Warner DS: Apoptosis is not enhanced in primary mixed neuronal/glial cultures protected by isoflurane against N-methyl-D-aspartate excitotoxicity. Anesth Analg 2004; 99:1708–14Wise-Faberowski, L Aono, M Pearlstein, RD Warner, DS
de Klaver MJ, Manning L, Palmer LA, Rich GF: Isoflurane pretreatment inhibits cytokine-induced cell death in cultured rat smooth muscle cells and human endothelial cells. Anesthesiology 2002; 97:24–32de Klaver, MJ Manning, L Palmer, LA Rich, GF
Kawaguchi M, Drummond JC, Cole DJ, Kelly PJ, Spurlock MP, Patel PM: Effect of isoflurane on neuronal apoptosis in rats subjected to focal cerebral ischemia. Anesth Analg 2004; 98:798–805Kawaguchi, M Drummond, JC Cole, DJ Kelly, PJ Spurlock, MP Patel, PM
Gray JJ, Bickler PE, Fahlman CS, Zhan X, Schuyler JA: Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+and mitogen-activated protein kinases. Anesthesiology 2005; 102:606–15Gray, JJ Bickler, PE Fahlman, CS Zhan, X Schuyler, JA
Kvolik S, Glavas-Obrovac L, Bares V, Karner I: Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci 2005; 77:2369–83Kvolik, S Glavas-Obrovac, L Bares, V Karner, I
Loop T, Dovi-Akue D, Frick M, Roesslein M, Egger L, Humar M, Hoetzel A, Schmidt R, Borner C, Pahl HL, Geiger KK, Pannen BH: Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro  . Anesthesiology 2005; 102:1147–57Loop, T Dovi-Akue, D Frick, M Roesslein, M Egger, L Humar, M Hoetzel, A Schmidt, R Borner, C Pahl, HL Geiger, KK Pannen, BH
Wei H, Kang B, Wei W, Liang G, Meng QC, Li Y, Eckenhoff RG: Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res 2005; 1037:139–47Wei, H Kang, B Wei, W Liang, G Meng, QC Li, Y Eckenhoff, RG
Matsuoka H, Kurosawa S, Horinouchi T, Kato M, Hashimoto Y: Inhalation anesthetics induce apoptosis in normal peripheral lymphocytes in vitro  . Anesthesiology 2001; 95:1467–72Matsuoka, H Kurosawa, S Horinouchi, T Kato, M Hashimoto, Y
Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE: A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 2000; 6:397–404Lu, DC Rabizadeh, S Chandra, S Shayya, RF Ellerby, LM Ye, X Salvesen, GS Koo, EH Bredesen, DE
Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, Koo EH, Bredesen DE: Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem 2002; 82:283–94Galvan, V Chen, S Lu, D Logvinova, A Goldsmith, P Koo, EH Bredesen, DE
Kovacs DM, Mancini R, Henderson J, Na SJ, Schmidt SD, Kim TW, Tanzi RE: Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer’s disease mutations in human neuroglioma cells. J Neurochem 1999; 73:2278–85Kovacs, DM Mancini, R Henderson, J Na, SJ Schmidt, SD Kim, TW Tanzi, RE
Holtzman DM, Deshmukh M: Caspases: A treatment target for neurodegenerative disease? Nat Med 1997; 3:954–5Holtzman, DM Deshmukh, M
Lunkes A, Trottier Y, Mandel JL: Pathological mechanisms in Huntington’s disease and other polyglutamine expansion diseases. Essays Biochem 1998; 33:149–63Lunkes, A Trottier, Y Mandel, JL
Namura S, Zhu J, Fink K, Endres M, Srinivasan A, Tomaselli KJ, Yuan J, Moskowitz MA: Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci 1998; 18:3659–68Namura, S Zhu, J Fink, K Endres, M Srinivasan, A Tomaselli, KJ Yuan, J Moskowitz, MA
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
Fig. 1. Two percent isoflurane induces caspase-3 activation, decreases the levels of amyloid precursor protein C-terminal fragments (APP-CTFs), and increases amyloid β protein (Aβ) levels in H4 amyloid precursor protein full-length (APP-FL) cells. (  A  ) The 2% isoflurane treatment (  lanes 4–6  ) induces caspase-3 cleavage (activation) as compared with control conditions (  lanes 1–3  ) in H4-APP-FL cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-FL cells. (  B  ) The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. (  C  ) Cell viability assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) study in H4-APP-FL cells. The 2% isoflurane treatment (  black bar  ) decreases cell viability as compared with control conditions (  white bar  ) in H4-APP-FL cells. (  D  ) The 2% isoflurane treatment (  lanes 3 and 4  ) renders a visible reduction in APP-CTF levels as compared with control conditions (  lanes 1 and 2  ). (  E  ) Quantitation of the Western blot shows that 2% isoflurane treatment (  black bar  ) decreases the ratio of APP-CTFs to APP-FL as compared with control conditions (  white bar  ), normalized to β-actin levels, in H4-APP-FL cells. (  F  ) Two percent isoflurane (  black bar  ) increases both Aβ40and Aβ42levels as compared with control conditions (  white bar  ) in H4-APP-FL cells. Data are mean ± SD; n = 9–10 for each experimental group. A  t  test is used to compare the difference between control conditions and the 2% isoflurane treatment condition: *  P  < 0.05, **  P  < 0.01. 
×
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
Fig. 2. Aβ antibodies (6E10 and 4G8) do not inhibit caspase-3 activation induced by 2% isoflurane. (  A  ) Two percent isoflurane (  lanes 3 and 4  ) causes caspase-3 activation as compared with control conditions (  lanes 1 and 2  ). Benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD; 100 μm) treatment (  lanes 5 and 6  ), but not Aβ antibody 6E10 (50 ng/ml) plus 4G8 (50 ng/ml) treatment (  lanes 7 and 8  ), inhibits the caspase-3 activation induced by 2% isoflurane. There is no significant difference in the amounts of β-actin in the control conditions, 2% isoflurane–, 2% isoflurane plus Z-VAD–, or 2% isoflurane plus 6E10 and 4G8–treated H4 amyloid precursor protein full-length cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. The 2% isoflurane treatment (  black bar  ) increases caspase-3 activation as compared with control conditions (  white bar  ), normalized to β-actin levels. The caspase-3 activation is inhibited by Z-VAD (  gray bar  ), but not by 6E10 plus 4G8 (  net bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions plus saline and 2% isoflurane plus saline (or 6E10 and 4G8) treatment: **  P  < 0.01, and the difference between 2% isoflurane plus saline treatment and 2% isoflurane plus Z-VAD treatment: ##  P  < 0.01. 
×
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
Fig. 3. Isoflurane induces caspase-3 activation in H4 amyloid precursor protein C-99 fragment (H4-APP-C99) cells. (  A  ) Two percent isoflurane treatment (  lanes 3 and 4  ) induces caspase-3 cleavage (activation) as compared with the control conditions (  lanes 1 and 2  ) in H4-APP-C99 cells. There is no significant difference in the amounts of β-actin in the control conditions or 2% isoflurane–treated H4-APP-C99 cells. (  B  ) Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to caspase-3 full-length (FL) in the Western blots. Treatment with 2% isoflurane (  black bar  ) increases caspase-3 activation compared with control conditions (  white bar  ), normalized to β-actin levels. Data are mean ± SD; n = 4 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment: **  P  < 0.01. 
×
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
Fig. 4. N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) potentiates isoflurane-induced caspase-3 activation and increases amyloid precursor protein C-terminal fragment (APP-CTF) levels. (  A  ) Treatment with 2% isoflurane plus dimethyl sulfoxide (DMSO) (  lanes 5 and 6  ) induces caspase-3 activation as compared with control conditions plus DMSO treatment (  lanes 1 and 2  ) or the control conditions plus DAPT treatment (  lanes 3 and 4  ). Treatment with 2% isoflurane plus DAPT (  lanes 7 and 8  ) causes more degree of casepase-3 activation and increases in the levels of APP-CTFs (detected by antibody A8717) and APP-C99 (detected by antibody 6E10) as compared with the 2% isoflurane plus DMSO treatment (  lanes 5 and 6  ). There is no significant difference in the amounts of β-actin in all of the above treatments. (  B  ) Quantitation of the Western blots shows that the 2% isoflurane plus DAPT treatment (  net bar  ) causes more increase in caspase-3 activation and in levels of APP-CTFs and APP-C99 as compared with 2% isoflurane plus DMSO treatment (  black bar  ), normalized to β-actin levels. Data are mean ± SD; n = 6 for each experimental group. A  t  test is used to compare the difference between control conditions and 2% isoflurane treatment, or between DAPT treatment and DMSO treatment: *  P  < 0.05, **  P  < 0.01, and the difference between 2% isoflurane plus DMSO and 2% isoflurane plus DAPT: #  P  < 0.05, ##  P  < 0.01. FL = full-length. 
×